Skip to content

Decoy Therapeutics Inc.: 10-Q filed 2025-11-14

What Decoy Therapeutics Inc. reported in its quarterly report filed 2025-11-14 (fiscal Q3 2025): 28 published measures, 86 facts as tagged in accession 0001615219-25-000164.

This filing

Form
10-Q (quarterly report)
Filed
2025-11-14
Fiscal period
fiscal Q3 2025
Accession
0001615219-25-000164 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All Decoy Therapeutics Inc. filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2025-09-306,097,032USD
At 2024-12-313,022,974USD

Total liabilities

Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.

PeriodValueUnitDays
At 2025-09-301,848,967USD
At 2024-12-311,511,279USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2025-09-304,248,065USD
At 2025-06-30-829,724USD
At 2025-03-3161,866USD
At 2024-12-311,511,695USD
At 2024-09-302,924,583USD
At 2024-06-302,375,353USD
At 2024-03-313,649,538USD
At 2023-12-315,287,282USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2025-09-304,809,680USD
At 2024-12-312,434,528USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-873,467USD92
2025-01-01 to 2025-09-30-3,540,825USD273
2025-04-01 to 2025-06-30-957,825USD91
2025-01-01 to 2025-03-31-1,709,533USD90
2024-07-01 to 2024-09-30-972,121USD92
2024-01-01 to 2024-09-30-4,111,844USD274
2024-04-01 to 2024-06-30-1,424,433USD91
2024-01-01 to 2024-03-31-1,715,290USD91

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-3,690,700USD273
2024-01-01 to 2024-09-30-3,782,819USD274

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2025-01-01 to 2025-09-306,265,852USD273
2024-01-01 to 2024-09-301,166,938USD274

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2025-01-01 to 2025-09-30-200,000USD273
2024-01-01 to 2024-09-300USD274

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2025-09-30-85,464,443USD
At 2024-12-31-81,923,618USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2025-07-01 to 2025-09-30481,587shares92
2025-01-01 to 2025-09-30246,741shares273
2024-07-01 to 2024-09-3085,458shares92
2024-01-01 to 2024-09-3053,426shares274

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2025-07-01 to 2025-09-30481,587shares92
2025-01-01 to 2025-09-30246,741shares273
2024-07-01 to 2024-09-3085,458shares92
2024-01-01 to 2024-09-3053,426shares274

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.81USD/shares92
2025-01-01 to 2025-09-30-14.35USD/shares273
2024-07-01 to 2024-09-30-11.38USD/shares92
2024-01-01 to 2024-09-30-76.96USD/shares274

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-1.81USD/shares92
2025-01-01 to 2025-09-30-14.35USD/shares273
2024-07-01 to 2024-09-30-11.38USD/shares92
2024-01-01 to 2024-09-30-76.96USD/shares274

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2025-01-01 to 2025-09-3079,535USD273
2024-01-01 to 2024-09-30222,685USD274

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2025-07-01 to 2025-09-30-895,130USD92
2025-01-01 to 2025-09-30-3,579,390USD273
2024-07-01 to 2024-09-30-1,006,471USD92
2024-01-01 to 2024-09-30-4,245,603USD274

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2025-09-306,064,938USD
At 2024-12-312,987,562USD

Current accounts payable

Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.

PeriodValueUnitDays
At 2025-09-301,104,184USD
At 2024-12-31936,994USD

Operating expenses

Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.

PeriodValueUnitDays
2025-07-01 to 2025-09-30895,130USD92
2025-01-01 to 2025-09-303,579,390USD273
2024-07-01 to 2024-09-301,006,471USD92
2024-01-01 to 2024-09-304,245,603USD274

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2025-07-01 to 2025-09-3061,826USD92
2025-01-01 to 2025-09-30253,741USD273
2024-07-01 to 2024-09-30137,234USD92
2024-01-01 to 2024-09-30594,683USD274

Common shares outstanding

Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.

PeriodValueUnitDays
At 2025-09-30944,491shares
At 2024-12-3196,077shares

Cash including restricted cash

Cash, cash equivalents and restricted cash as reported in the cash flow reconciliation. Restricted amounts are not freely available, so this is not the same as unrestricted cash.

PeriodValueUnitDays
At 2025-09-304,809,680USD
At 2024-12-312,434,528USD
At 2024-09-303,284,029USD
At 2023-12-315,899,910USD

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2025-09-3089,712,414USD
At 2024-12-3183,435,303USD

Other noncurrent assets

Noncurrent assets the filer does not present separately. The composition differs by filer and is described only in the filing.

PeriodValueUnitDays
At 2025-09-3032,094USD
At 2024-12-3135,412USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2025-09-301,255,258USD
At 2024-12-31553,034USD

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2025-07-01 to 2025-09-30833,304USD92
2025-01-01 to 2025-09-303,325,649USD273
2024-07-01 to 2024-09-30869,237USD92
2024-01-01 to 2024-09-303,650,920USD274

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2025-01-01 to 2025-09-303,318USD273
2024-01-01 to 2024-09-303,318USD274

Interest paid, net

Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.

PeriodValueUnitDays
2025-01-01 to 2025-09-305,800USD273
2024-01-01 to 2024-09-3012,064USD274

Change in accounts payable

The cash flow adjustment for the change in payables during the period. A positive value under this concept means payables grew and added to operating cash flow.

PeriodValueUnitDays
2025-01-01 to 2025-09-3027,132USD273
2024-01-01 to 2024-09-30-437,052USD274

Inspect the source

Entity
Decoy Therapeutics Inc. / CIK 0001615219
Captured
2026-09-21T17:20:32.388Z
SEC response SHA-256
3dae29679ef228e32bff301a79640d7e283fcc5b87c08a4882faedfce1c66e98

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001615219.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))